Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity

Author(s): Hinrich Abken, Andreas Hombach, Claudia Heuser

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 24 , 2003

Become EABM
Become Reviewer
Call for Editor


The application of immunotherapy for the treatment of malignant diseases has attracted growing interest in recent years. Because T-cell immunity plays a major part in the control of tumor growth, strategies have been developed to specifically target and activate T-cells towards tumor cells by circumventing major histocompatibility complex (MHC)- restricted antigen recognition. Here we review the immunoreceptor (“T-body”) strategy based on grafting cytolytic T-cells with an antigen-specific, recombinant receptor with signalling properties. The extracellular domain of the receptor molecule consists of a single-chain antibody fragment (scFv) derived from a monoclonal antibody that binds to a tumor associated antigen. The intracellular domain is derived from a signalling receptor for cellular activation, e.g., the FcεRI receptor γ-chain or the CD3 σ-chain. Thereby, the immunoreceptor strategy combines the advantages of MHCindependent binding of antibodies to antigens with efficient T-cell activation. Due to the receptor design, T-cells grafted with immunoreceptors can be directed virtually against every cell defined by the particular antigen, including tumor cells and virally infected cells. This review summarizes the current knowledge about redirecting T-cell functions by grafting in recombinant immunoreceptors with specificity for tumor associated antigens and discusses the limitations and perspectives of the strategy for use in adoptive immunotherapy of malignant diseases.

Keywords: immunoreceptor, recombinant tcr, costimulation, tumor-specific t-cells, immunotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [1992 - 2001]
Pages: 10
DOI: 10.2174/1381612033454289
Price: $65

Article Metrics

PDF: 7